You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The program is in its third year monitoring individuals with these mutations to try to detect disease early, understand their risk, and develop preventive treatments.
The firm is hoping that researcher-generated data will soon be published in peer-reviewed papers, while it weathers the COVID-19 pandemic.
Mission Bio will use a recent $70 million funding round to develop quality control assays using its Tapestri single-cell analysis platform.
The immune sequencing firm also provided an update on the development of its ImmunoSeq Dx clinical product for detecting prior infection with SARS-CoV-2.
The sequencing-based test for minimal residual disease can be use with blood and bone marrow samples in patients with chronic lymphocytic leukemia.
Transcriptomic and multi-omic data spanning more than 10,000 samples helped map "immunogenomic" interactions that may inform treatment outcomes and targets.
In Genome Biology this week: analysis of B cells that interact with non-small cell lung cancer tumors, population genomic analysis of Eubacterium rectale, and more.
In PNAS this week: genetic variants linked to a pediatric periodic fever syndrome, TERT promoter mutations influencing BRAF and MEK inhibitor response, and more.
The study will compare whole-genome sequencing and RNA sequencing to conventional diagnostic methods in about 450 acute leukemia patients in Sweden.
The firm has received a supplemental approval that provides its customers with an option to purchase its IVD-labeled FLT3 mutation assay for in-house testing.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.